UCSF looks for partners on breast cancer biomarkers

The University of California, San Francisco, is looking for partners to help develop biomarkers for early detection of a highly aggressive subtype of breast cancer. The markers indicate the presence of triple negative breast cancer (TNBC), so-called because it lacks expression of the estrogen and progesterone receptors and displays moderate levels of the human epidermal growth factor receptor 2 (HER2), according to the tech transfer website of UCSF.

"This highly aggressive cancer subtype is of particular clinical interest because there are no targeted therapies for its treatment, making early detection a priority," the site says.

Researchers have identified a set of glycosites and their corresponding glycoproteins that may be detectable in blood from patients with TNBC. The discovery could lead to an easy and sensitive blood test and monitoring of therapeutic responses, the tech transfer office says.

- read more on the UCSF tech transfer site

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.